This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about E3 ubiquitin-protein ligase UBR2.
Plays a critical role in chromatin inactivation and chromosome-wide transcriptional silencing during meiosis through ubiquitination of histone H2A. Binds leucine and is a negative regulator of the leucine-mTOR signaling pathway, thereby controlling cell growth.
Human | |
---|---|
Gene Name: | UBR2 |
Uniprot: | Q8IWV8 |
Entrez: | 23304 |
Belongs to: |
---|
UBR1 family |
bA49A4.1; C6orf133MGC71112; chromosome 6 open reading frame 133; dJ242G1.1; dJ392M17.3; DKFZp686C08114; E3 ubiquitin-protein ligase UBR2; EC 6.3.2.-; KIAA0349FLJ36357; N-recognin-2; RP3-392M17.3; ubiquitin protein ligase E3 component n-recognin 2; Ubiquitin-protein ligase E3-alpha-2; Ubiquitin-protein ligase E3-alpha-II
Mass (kDA):
200.538 kDA
Human | |
---|---|
Location: | 6p21.1 |
Sequence: | 6; NC_000006.12 (42563954..42693505) |
Broadly expressed, with highest levels in skeletal muscle, kidney and pancreas. Present in acinar cells of the pancreas (at protein level).
Nucleus. Associated with chromatin during meiosis.
In biological assays, UBR2 markers are commonly used to detect specific proteins. These antibodies can be polyclonal or monoclonal and are reactive with UBR2 in a wide variety of samples from animals. The antibodies developed by Boster Bio are based on rabbit and mouse models and recognize E3 ubiquitin-protein ligase (Ubpl), which binds to proteins with a specific N-terminal residue. The ligase recognizes proteins with a particular N-terminal residue and ubiquitinates or degrades the proteins.
Boster Bio produces a range of high-quality, validated antibodies and reagents. The Boster Bio lab produces primary antibodies, ELISA kits, and reagents for a wide range of applications, including neuroscience. In addition, Boster offers a free secondary antibody with the purchase of any primary antibody. All of Boster's products are designed to be highly efficient for ELISA or WB assays, and all of them are guaranteed to work as advertised.
As with any research, it is important to publish evidence of primary antibody validation. It is also helpful to include the raw data for facilitating peer review. The information you provide should include the characteristics of your primary antibody, including its dilutions, incubation time, and positive and negative controls. You should also include the cell type and organism/species for which the antibody was generated. To ensure the validity of your primary antibody, follow consistent publication practices.
While many studies have shown that primary antibodies have a high level of specificity, it is important to check the specific antibody's recognition in your intended assay. If you find additional bands, this may indicate that the antibody is not targeting its target. To ensure high-quality antibodies, ensure that the antibody manufacturer follows strict guidelines to maintain the highest standards. If you need to perform a sensitive test on a specific protein, the Boster Primary Antibody can provide it.
To ensure reproducibility of antibodies, the user, publisher, and vendor must collaborate. Users must validate the antibody's performance through well-designed experiments. The vendor must provide high-quality antibodies and detailed documentation of their methods. Finally, the publisher can enforce guidelines for antibody validation. The three parties should work together to standardize this process. There are no shortcuts to reproducibility, so it is imperative that all three parties work together to achieve it.
In addition to performing quality checks, an antibody's performance must be tested in an assay relevant to the research it supports. For example, Western blotting validation is vital in determining the antibody's specificity and reproducibility. Hence, it is crucial to ensure the performance of the antibody in complementary assays to avoid false positives. The Boster Primary Antibodies should be validated with a complementary method to determine if the effect is caused by a specific compound.
Boster Bio UBR2 markers are a high-affinity protein derived from equine thymus tissue. These antibodies are used for biological assays and research purposes. They have been validated for use in immunohistochemistry, Western blotting, and ELISA. In this study, the company used these antibodies to detect E-cadherin and Twist expression in PCa cells.
Boster Bio manufactures primary antibodies and ELISA kits to improve your research and ensure its success. Boster's antibodies are optimized for WB and ELISA applications and come with the unique quality assurance guarantee. You can order a free secondary antibody with the purchase of your primary antibody. The Boster Bio product range includes antibodies for human and mouse samples. For the best results, choose Boster products.
Primary antibodies are immunoglobulins that recognize specific antigens. The quality of primary antibodies depends on the specificity and affinity. The stronger the affinity, the better the antibody will recognize its antigen. Poor specificity indicates the antibody's ability to bind to unintended antigens. Quality primary antibodies can be used to detect, purify, and measure the antigen of interest.
In immunocytochemistry, a transfected cell is processed to label a fluorescent protein. The primary antibody should colocalize with GFP to identify one protein. However, colocalization means that the labels are in the same spot, not that they bind to the same protein. This is because a light microscope's resolution is not high enough to discern a single protein.
As a primary-secondary antibody system, the UBR2 marker offers the benefit of dual-labeling specimens. With dual-labeling, researchers can ask more questions of specimens. The resulting answers are more robust and contextual. They are ideal for determining a particular disease's prevalence. So, why is the UBR2 marker such a good choice for research?
For the most accurate results, the antigen must be close to the site where the antibody is detected. To do this, a cell must be transfected with the antigen. This allows the researchers to determine the concentration of the antigen that saturates the antibody, leaving no unbound primary antibodies. When this is achieved, the antigen protein can be detected in high concentrations.
PMID: 15548684 by Kwak K.S., et al. Regulation of protein catabolism by muscle-specific and cytokine- inducible ubiquitin ligase E3alpha-II during cancer cachexia.
PMID: 15317757 by Yin J., et al. RECQL4, mutated in the Rothmund-Thomson and RAPADILINO syndromes, interacts with ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway.